Basic/Clinical Science Session
Cardiovascular-Kidney-Metabolic Interactions and More: Multimorbidity and the Era of Integrated Care, Including the Barry M. Brenner, MD, Endowed Lectureship
November 06, 2025 | 02:00 PM - 04:00 PM
Location: General Assembly C, Convention Center
Session Description
The understanding of diabetes and its complications has shifted in recent years, leading to greater integration of care in diabetes management, including the use of the term "cardiovascular-kidney-metabolic," or CKM. This session provides an overview of physiological and therapeutic interactions between the kidneys and other organ systems, with a focus on the eyes, liver, and rheumatological factors.
Note: Continuing education credits are not being offered for this session.
ASN gratefully acknowledges Monarch Pharmaceuticals for support of the Brenner Endowed Lectureship.
Learning Objective(s)
- Discuss the evolution of SGLT2 inhibitor use from "diabetes" drugs to cardiorenal protective therapy
- Summarize kidney-eye complications and therapies
- Identify kidney-liver pharmacotherapies
- Describe the field of rheuma-nephrology in the protection of bones, joints, and nephrons
Learning Pathway(s)
- Diabetic Kidney Disease
- Pharmacology
Moderators
Presentations
- SGLT2 Inhibitor Journey: From Metabolism to Kidney and Heart Protection: The Barry M. Brenner, MD, Endowed Lectureship
02:00 PM - 02:30 PM
- Nephrology and Eye Care in Diabetes
02:30 PM - 03:00 PM
- Kidney-Liver Pharmacotherapies: What Is the State of the Art?
03:00 PM - 03:30 PM
- Rheuma-Nephrology: Protecting Bones, Joints, and Nephrons
03:30 PM - 04:00 PM